Can haploidentical transplantation meet all patients' needs?

Area of Science:

• Hematopoietic Stem Cell Transplantation (HSCT)
• Immunology
• Oncology

Background:

• Allotransplantation without an HLA-matched sibling donor involves choices like unrelated donors and umbilical cord blood.
• Haploidentical transplantation has gained popularity, particularly with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis.

Purpose of the Study:

• To review current donor and graft options in allogeneic HSCT.
• To discuss the impact of novel strategies like PTCy and graft source on GVHD.
• To highlight the need for tailored decision-making based on patient-specific factors.

Main Methods:

• Review of current literature and clinical practices in allogeneic HSCT.
• Analysis of outcomes associated with different donor sources (unrelated, cord blood, haploidentical).
• Evaluation of GVHD prophylaxis strategies, including PTCy and graft type (bone marrow vs. peripheral blood stem cells).

Main Results:

• Multiple donor options exist for HSCT when a matched sibling is unavailable.
• PTCy effectively reduces GVHD risk, while bone marrow grafts may lower chronic GVHD compared to peripheral blood stem cells.
• Current evidence does not demonstrate clear superiority of one approach over others; outcomes are influenced by various factors.

Conclusions:

• Advances in HSCT, including PTCy and graft selection, have improved patient outcomes.
• Both PTCy and bone marrow grafts show promise in mitigating GVHD.
• Future research should focus on prospective data to guide individualized HSCT strategies based on patient risk and comorbidity.